		<del>-</del>		Attorney Docket No.:					
DIVISION - CO APP	A-7	748F							
Anticipated Classification Of This Application: Prior Application:									
c	lass	Subclass	Examine		Art Unit				
			V.	Balasubramanian	1624				
To the Commissioner for Patents:  This is a request for filling a  continuation  continuation continuation-in-part application, under 37 CFR 1.53(b),									
of pending prior application Serial No. 09/685,053 filed on October 6 , 20 00 ,  of Armistead et al.  for KINASE INHIBITORS  For CONTINUATION or DIVISIONAL APPLNs only: The entire disclosure of the prior application, from which an oath or declaration is supplied Ounder Box 1b, below, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  1. Transmitted herewith are:  354 pages of specification, 14 pages of claim(s) and 1 page of abstract, totaling 369 pages.  sheet(s) of drawings.  8 pages of Oath or Declaration by the applicant(s):  a. Newly executed (original or copy)  b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional applns. only)									
pages of Sequence Listing; computer readable copy (identical to paper copy); sequence statement.									
2. The filing fee is calculated below:									
For	Number Filed	Number Extra		Rate	Fee				
Total Claims	191 - 20		Х	\$18.00 =	\$3,078.00				
Independent Claims	1 - 3	= 0	х	\$86.00 =	0.00				
Multiple Dependent Claims	8		+	\$290.00 =	290.00				
Basic Fee				\$770.00 =	770.00				
				Total Filing Fee	\$4,138.00				
<ol> <li>Please charge Deposit Account No. 01-0519, in the name of Amgen Inc., in the amount of \$4,138.00. An original and one copy are enclosed.</li> <li>Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.</li> <li>The Commissioner is hereby authorized to charge any additional filing fees which may be required by the accompanying application, any additional fees which may be required during pendency of this application as required by 37 CFR 1.16 or 1.17, or credit any overpayment to Deposit Account No. 01-0519 throughout the prosecution of this application.</li> <li>Cancel in this application original claims</li> </ol>									
of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)  EXPRESS MAIL CERTIFICATE									
		Date of Deposit:	fice to Addressee	October 31, 2003  * service under 37 CFR 1.10 on the da	Wer-				

Docket No.: A-748F

7. 🛛	Preliminarily	, pleaso	e amend the specificatio	n by inserting before t	the first line the followir	ıg:			
			continuation  dhereby incorporated by re		erial No09/685,053	, filed <u>October 6,</u>			
8. 🗌	Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)								
8a. 🗌	New forma	New formal drawings are enclosed.							
9. 🗌	Priority of application Serial No. is claimed under 35 USC 119.			filed on	in	(country)			
9a. 🗌	The certified copy has been filed in prior application Serial No.				filed				
10. 🛚	The prior application is assigned of record to Amgen Inc.								
11. 🔲	11. A preliminary amendment is enclosed.								
12. 🛚	Also enclos	ed	Information Disclosure S	tatement, Form 1449					
13. 🗌	Other: _					190-1111			
14. 🛚		The po	wer appears in the origina the power does not appea plication is enclosed.	Il papers in the prior app Ir in the original papers,		·····			
	с. 📙		ss all future communicatio	ns to					
	Signator:	at th	e address below.  Assignee of complete int	erest					
			Attorney or agent of reco	ord	Joseph W. Bulock Attorney/Agent for App Registration No. 37,10 Phone: (805) 447-796	03 6			
Please s	end all future o	orrespo	endence to:		Date: October 31, 200	s			
U. S. Patent Operations/JWB Dept. 4300, M/S 27-4-A AMGEN, INC. One Amgen Center Drive Thousand Oaks, California 91320-1799, USA			21069 PATENT TRADEMARK OFFI	СБ					